Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AsiDNA + Talazoparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AsiDNA||AsiDNA is an oligodeoxyribonucleotide drug that acts as a DNA repair pathway antagonist by mimicking double-stranded DNA breaks and subsequently recruiting DNA repair proteins, thereby preventing the repair of other DNA damaged sites, and thus, potentially leading to increased cell death and inhibition of cell proliferation (PMID: 27559053, PMID: 32839491).|
|Talazoparib||Talzenna||BMN673||PARP Inhibitor (Pan) 20||Talzenna (talazoparib) is an inhibitor of PARP1 and PARP2, which prevents the DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis, and leads to lethality in homologous recombination repair deficient cells (PMID: 28242752). Talzenna (talazoparib) is FDA approved for use in patients with ERBB2 (HER2)-negative breast cancer harboring deleterious or suspected deleterious germline BRCA mutations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||breast cancer||not applicable||AsiDNA + Talazoparib||Preclinical - Cell culture||Actionable||In a preclinical study, AsiDNA and Talzenna (talazoparib) combination treatment resulted in increased cell death and inhibition of proliferation in breast cancer cell lines compared to Talzenna (talazoparib) alone in culture (PMID: 27559053).||27559053|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|